Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02658929 · ClinicalTrials.gov registry record · Phase 1
Study of bb2121 in Multiple Myeloma
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT02658929 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 67 participants.
The verdict
NCT02658929, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM).
Interventions
- BIOLOGICAL bb2121
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2015-12-22 |
| Est. Completion | 2022-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02658929
The ClinicalTrials.gov registry entry for NCT02658929 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bb2121 is the first listed.
NCT02658929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02658929 about?
NCT02658929 is a clinical study titled "Study of bb2121 in Multiple Myeloma". Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM).
What is the current status of trial NCT02658929?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2015-12-22. Estimated completion is 2022-09-22.
What interventions are being tested in trial NCT02658929?
The interventions under investigation include: bb2121 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02658929?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.